NanoCytomics is dedicated to advancing cancer diagnostics through its innovative technologies, particularly focusing on non-invasive testing methods. The company is developing a platform that utilizes Partial Wave Spectroscopy (PWS) microscopy, which is designed to provide highly accurate and low-cost assessments of cancer risk. This technology aims to enhance the risk stratification of patients, enabling primary care physicians to identify individuals who may benefit from more definitive diagnostic procedures at an earlier stage. By doing so, NanoCytomics hopes to improve cancer survival rates significantly by facilitating timely interventions when treatments are most effective.

The company's approach is grounded in the concept of "Field Effect Technology," which allows for the detection of nanoscale changes in cellular architecture that may indicate the presence of cancer. This technology serves as a "fingerprint" for risk discovery, providing critical insights into the biological changes associated with various cancers, including lung and colon cancer. Through ongoing research and development, NanoCytomics is committed to contributing to the medical community's understanding of cancer detection and prevention, ultimately aiming to help millions of people survive cancer through early and accurate diagnosis.

United States

NanoCytomics is a biotechnology company that offers PWS Screening for the early detection of various high incidence cancers, providing a simple and effective process for physicians and patients.

NanoCytomics

Company Details